Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Tolerability of Laquinimod
- Study Title
- A Multinational, Randomized, Double-blind, ParFemale, Maleel-group, Placebo-controlled Study Assessing the Safety and Tolerability
- Teva Identifier
- LAQ-MS-201
- ClinicalTrials.gov Identifier
- NCT01404117
- Study Status
- Withdrawn
- Trial Condition(s)
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Laquinimod 0.6 | Drug: Laquinimod 1.2 | Other: Glatiramer Acetate or interferon-beta+ Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 55 Years
- Trial Duration
- 03/01/2012 - 01/01/2014
- Phase
- Phase 2
